Blood Advances2020ReviewNon-viral Gene Delivery
Annika M. Frank, Angela H. Braun, Lea Scheib, Shivani Agarwal, Irene C. Schneider, Floriane Fusil, Severine Perian, Ugur Sahin, Frederic B. Thalheimer, Els Verhoeyen, Christian J. Buchholz
Conventional lentiviral vectors (LVs) are not selective for T cells and cannot efficiently transduce resting or minimally stimulated T lymphocytes, which limits their use for direct in vivo T-cell gene delivery. There is a need for vectors that can both target T cells specifically and activate them sufficiently to…
Read the article →PNAS* (*Proceedings of the National Academy of Sciences*)2020ReviewNon-viral Gene Delivery
Stephany Y. Tzeng, Kisha K. Patel, David R. Wilson, Randall A. Meyer, Kelly R. Rhodes, Jordan J. Green
Cancer immunotherapy has shown clinical success but remains limited by low response rates, high cost, and the need for ex vivo cell manipulation or prior knowledge of patient-specific tumour antigens. A broadly applicable, antigen-agnostic strategy that genetically reprograms tumour cells in situ—without ex vivo…
Read the article →2020ReviewNon-viral Gene Delivery
Zeb A, Rana I, Choi H-I, Et Al.
Biopharmaceuticals have become clinically and commercially important due to their specificity, potency, targeting ability, and reduced side effects, but their macromolecular structure and intrinsic instability make formulation and administration challenging; parenteral delivery remains the only viable option in most…
Read the article →Nature Reviews Drug Discovery.2019ReviewNon-viral Gene Delivery
Rachel S. Riley, Carl H. June, Robert Langer, Michael J. Mitchell.
Immunotherapy has become powerful but broad implementation limited by inability to control immune modulation; serious adverse effects including autoimmunity, nonspecific inflammation. Need delivery technologies to improve efficacy and safety. Numbers.
Read the article →Nature Reviews Immunology2019ReviewNon-viral Gene Delivery
Søren R. Paludan, Line S. Reinert, Veit Hornung
DNA in abnormal cellular compartments (cytosol, endosomes, micronuclei) is a potent danger signal for the innate immune system, primarily known for inducing type I interferons and IL-1β. More recently, it has become clear that cytosolic DNA also triggers various forms of programmed cell death (PCD), but the pathways…
Read the article →2019ReviewNon-viral Gene Delivery
Majumder J, Et Al.
Conventional systemic drug administration suffers from low site-specific bioavailability, unfavourable biodistribution, poor target accumulation, and adverse side effects. There is a need for carrier-based systems that enable localised and targeted delivery, improve therapeutic efficacy, and reduce toxicity…
Read the article →2019ReviewNon-viral Gene Delivery
Jin Q, Deng Y, Chen X, Ji J.
Ideal cancer nanomedicines need a stealth surface for prolonged circulation and tumour accumulation, but stealth surfaces often hinder cellular uptake. Conversely, cationic or targeting-ligand surfaces enhance uptake but cause rapid clearance and off-target interactions. This review addresses the central conflict…
Read the article →Biochimie2019ReviewDrug Delivery
Aqeel Ahmad, Javed Masood Khan, Shafiul Haque
Endosomal escape remains the rate-limiting step for efficient gene and drug delivery using nanoparticles (NPs). Despite continuous advancements, most NPs internalised via endocytic pathways are degraded by hydrolytic enzymes in lysosomes, severely limiting therapeutic efficacy. There is an unmet need to…
Read the article →Biomaterials Research2019ReviewDrug Delivery
Dhrisya Chenthamara, Sadhasivam Subramaniam, Sankar Ganesh Ramakrishnan, Swaminathan Krishnaswamy, Musthafa Mohamed Essa, Feng-Huei Lin, And M. Walid Qoronfleh
Despite enormous strides in nanotechnology research and development, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. There is a need to provide a comprehensive overview of commonly used nanomaterials, their core properties, surface…
Read the article →Biomaterials Science2019ReviewNon-viral Gene Delivery
Alidha Gafur, Natalia Kristi, Ali Maruf, Guixue Wang, And Zhiyi Ye
Despite decades of nanomedicine development for tumour therapy, less than 1% of systemically administered nanocarriers (NCs) accumulate in solid tumours. This is largely due to protein corona formation during blood circulation, which accelerates clearance and masks targeting ligands. Stealthy (neutral/negatively…
Read the article →Chemistry and Physics of Lipids2019ReviewNon-viral Gene Delivery
Scheideler M, Vidakovic I, Prassl R
miRNAs can regulate about 60% of protein-coding genes and enable targeting of previously “undruggable” proteins and diseases, but their clinical use is limited by nuclease degradation, poor tissue targeting, inefficient cellular uptake, and inadequate cytosolic release. Lipid nanocarriers are a versatile…
Read the article →Journal of King Saud University – Science2019ReviewDrug Delivery
Venditti, I
Polymeric nanocarriers such as dendrimers, micelles, nanoparticles, nanogels, nanocapsules, and vesicles are widely investigated for drug delivery, but their morphology, surface chemistry, and functionalisation strongly influence drug loading, controlled release, and targeting. This review addresses the need for a…
Read the article →Nanoscale2019ReviewDrug Delivery
Ferrari, R.; Sponchioni, M.; Morbidelli, M.; Moscatelli, D
Many polymer-based nanoparticle formulations fail before or during clinical trials. This review identifies the key checkpoints a nanocarrier must satisfy after intravenous injection — biocompatibility, drug loading/release, storage stability, biodistribution, target selectivity, cellular internalisation, and…
Read the article →Nature Reviews Drug Discovery2019ReviewNon-viral Gene Delivery
Ekliadious, I.; Colson, Y. L.; Grinstaff, M. W
Polymer–drug conjugates have achieved clinical success, especially PEG–protein conjugates, but translation of many conjugates—particularly polymer–small-molecule anticancer therapeutics—remains limited. This review addresses the need for rational design, better understanding of in vivo barriers, and identification of…
Read the article →Journal of Controlled Release.2018ReviewDrug Delivery
Hassan Dianat‐moghadam, Maryam Heidarifard, Rana Jahanban‐esfahlan, Yunes Panahi, Hamed Hamishehkar, Farhad Pouremamali, Reza Rahbarghazi, Mohammad Nouri
Cancer stem cells (CSCs) drive tumour heterogeneity, drug resistance, recurrence, and metastasis, limiting conventional chemo/radiotherapy. Liposomal drug delivery systems (LDDSs) are biocompatible, versatile nanocarriers that may overcome CSC-mediated resistance, but their clinical translation remains limited by…
Read the article →Annual Review of Chemical and Biomolecular Engineering2018ReviewNon-viral Gene Delivery
Karlsson, J.; Vaughan, H. J.; Green, J. J
Biodegradable polymeric nanoparticles have great potential to improve cancer therapy by enabling targeted delivery, triggered release, and reduced off-target toxicity. This review addresses how such nanocarriers can be engineered to overcome systemic, organ-level, and cellular barriers and to target cancer cells…
Read the article →Journal of Controlled Release.2017ReviewNon-viral Gene Delivery
Tapeinos C, Battaglini M, Ciofani G
Delivery of therapeutics to the CNS is severely limited by the blood–brain barrier (BBB). Polymeric and inorganic nanoparticles have shown utility but face toxicity, scalability, and organic-solvent concerns. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are biocompatible lipid-based…
Read the article →2017ReviewDrug Delivery
Liposomes are the first nano drug delivery systems successfully translated into clinical use, but many formulations still face limitations in biodistribution, toxicity, stability, and target selectivity. An updated review was needed to summarise liposome technologies, marketed clinical products, formulation aspects…
Read the article →Materials2017ReviewNon-viral Gene Delivery
Sun, X.; Wu, G.; Xu, C.; Ye, Q.; Wang, C
Periodontitis causes irreversible destruction of periodontal tissues, and regeneration requires biomaterials with suitable mechanical, degradation, and biological properties. PLGA is attractive for periodontal regeneration because of its biocompatibility, tunable degradation, and processability, but its…
Read the article →Advanced Drug Delivery Reviews2016ReviewDrug Delivery
Niu Z, Conejos-Sánchez I, Griffin Bt, O’driscoll Cm, Alonso Mj
Peptide and protein therapeutics are highly potent but mostly require parenteral administration because they are degraded in the gastrointestinal tract, poorly permeate the intestinal epithelium, and have low oral bioavailability. Lipid-based nanocarriers are a promising strategy to enable oral peptide delivery by…
Read the article →Advanced Drug Delivery Reviews2015ReviewNon-viral Gene Delivery
Yunching Chen, Dong-Yu Gao, Leaf Huang
miRNAs can simultaneously regulate multiple cancer-related genes, making them attractive therapeutic agents or targets. However, efficient, specific, and safe systemic delivery of therapeutic miRNAs in vivo remains a major challenge due to rapid degradation, poor tumour penetration, immunotoxicity, endosomal…
Read the article →2015ReviewNon-viral Gene Delivery
Xue Hy, Guo P, Wen W-C, Wong Hl
RNAi therapeutics such as siRNA and miRNA can potently and specifically silence almost any gene, but systemic delivery is limited by poor cell permeation, rapid nuclease degradation, immunogenicity, and lack of target specificity. Lipid-based nanocarriers are among the most biocompatible and clinically advanced…
Read the article →2015ReviewNon-viral Gene Delivery
Li, L.; Wei, Y.; Gong, C
Viral vectors are efficient but carry risks of immunogenicity, inflammatory reactions, recombination, limited DNA cargo capacity, and manufacturing difficulties. Non-viral polymeric vectors are safer and easier to produce, but their transfection efficiency remains much lower than viral vectors because of multiple…
Read the article →Cold Spring Harbor Perspectives in Biology2014ReviewNon-viral Gene Delivery
Satyajit Mayor, Robert G. Parton, Julie G. Donaldson
Clathrin-mediated endocytosis (CME) has long been the dominant paradigm for cellular uptake, but many endocytic pathways operate without clathrin. These clathrin-independent endocytic (CIE) pathways are increasingly recognised as distinct routes with different cargo selectivity, molecular machinery, kinetics, and…
Read the article →